RYTM insider 10b5-1 sales and option exercises disclosed

Rhea-AI Filing Summary

Rhythm Pharmaceuticals (RYTM) insider activity: Chief Human Resources Officer Pamela J. Cramer reported option exercises and open‑market sales. On 11/07/2025, she exercised 8,805 options at $19.02 and 10,546 options at $6.80, then sold 19,351 shares at a weighted average price of $98.8231. On 11/10/2025, she exercised 3,515 options at $6.80 and sold 3,515 shares at $100.00.

Following these transactions, directly held common shares were 20,814. The sales were effected under a Rule 10b5‑1 trading plan adopted on August 7, 2025.

Derivative updates: post‑exercise, option holdings were 5,257 at a $19.02 strike (expires 07/25/2031) and 7,035 and 3,520 at a $6.80 strike (expire 02/08/2032). The filing notes one option grant is fully vested and another vests in 16 equal quarterly installments from February 9, 2022.

Insider Trade Summary

Net Seller: 22,866 shares ($2,263,826)

Net Sell 8 txns

Insider Cramer Pamela J.

Role Chief Human Resources Officer

Sold 22,866 shs ($2.26M)

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	3,515	$0.00	--
Exercise	Common Stock	3,515	$6.80	$24K
Sale	Common Stock	3,515	$100.00	$352K
Exercise	Stock Options (Right to Buy)	8,805	$0.00	--
Exercise	Stock Options (Right to Buy)	10,546	$0.00	--
Exercise	Common Stock	8,805	$19.02	$167K
Exercise	Common Stock	10,546	$6.80	$72K
Sale	Common Stock	19,351	$98.8231	$1.91M

Holdings After Transaction: Stock Options (Right to Buy) — 3,520 shares (Direct); Common Stock — 24,329 shares (Direct)

Footnotes (1)

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025. The stock option is fully vested. The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cramer Pamela J.

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2025		M		8,805	A	$19.02	29,619	D
Common Stock	11/07/2025		M		10,546	A	$6.8	40,165	D
Common Stock	11/07/2025		S(1)		19,351	D	$98.8231	20,814	D
Common Stock	11/10/2025		M		3,515	A	$6.8	24,329	D
Common Stock	11/10/2025		S(1)		3,515	D	$100	20,814	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$19.02	11/07/2025		M			8,805	(2)	07/25/2031	Common Stock	8,805	$0	5,257	D
Stock Options (Right to Buy)	$6.8	11/07/2025		M			10,546	(3)	02/08/2032	Common Stock	10,546	$0	7,035	D
Stock Options (Right to Buy)	$6.8	11/10/2025		M			3,515	(3)	02/08/2032	Common Stock	3,515	$0	3,520	D

Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2025.

2. The stock option is fully vested.

3. The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Rhythm (RYTM) disclose?

The CHRO exercised options and sold shares: 11/07/2025 sales of 19,351 shares at $98.8231 and 11/10/2025 sale of 3,515 shares at $100.00.

How many Rhythm (RYTM) shares did the CHRO hold after the reported trades?

Directly held common shares were 20,814 following the 11/10/2025 transactions.

Were the Rhythm (RYTM) share sales under a 10b5-1 plan?

Yes. The sales were effected under a Rule 10b5‑1 trading plan adopted on August 7, 2025.

What option exercises did the Rhythm (RYTM) CHRO report?

Exercises included 8,805 at $19.02 on 11/07/2025 and 10,546 and 3,515 at $6.80 on 11/07/2025 and 11/10/2025, respectively.

What are the expirations of the exercised Rhythm (RYTM) options?

Options at $19.02 expire on 07/25/2031. Options at $6.80 expire on 02/08/2032.

Is any option fully vested for the Rhythm (RYTM) CHRO?

Yes. One stock option is noted as fully vested; another vests in 16 equal installments from February 9, 2022.